Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands.
Faivre
Sandrine
S
Raymond
Eric
E
Casiraghi
Odile
O
Temam
Stéphane
S
Berthaud
Patrice
P
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001549:Benzamides; D003528:Carcinoma, Adenoid Cystic / Q000188:drug therapy* / Q000473:pathology; D004252:DNA Mutational Analysis; D020869:Gene Expression Profiling; D006801:Humans; D000068877:Imatinib Mesylate; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D019009:Proto-Oncogene Proteins c-kit / Q000032:analysis / Q000096:biosynthesis*; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D012468:Salivary Gland Neoplasms / Q000188:drug therapy* / Q000473:pathology
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit